

[Ethambutol + isoniazid + pyrazinamide + rifampicin](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines](#)

Codes ATC: [J04AM06](#)

Indication

Tuberculosis Code ICD11: [1B4Z](#)

INN

Ethambutol + isoniazid + pyrazinamide + rifampicin

Type de médicament

Chemical agent

Type de liste

Liste de base

Additional notes

WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

Formulations

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Historique des statuts LME

Ajouté pour la première fois en 1999 ([TRS 895](#))

Modifié en 2007 ([TRS 950](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Ethambutol + isoniazid + pyrazinamide + rifampicin](#)

[DrugBank](#)

[Ethambutol](#),

[Isoniazid](#),

[Pyrazinamide](#),

[Rifampicin](#)

Résumé des preuves et recommandation du comité d'experts

The EMLC Subcommittee did not endorse the inclusion of this fixed-dose combination for the treatment of tuberculosis on the EMLC. The various fixed-dose combinations were considered as a group, as there is no clinical evidence for any of these combinations in children. However, it is difficult to determine the necessary appropriate combinations and what the strengths of the components should be in FDCs for use in children without examining further data (including pharmacokinetic data, stratified by weight and age). The Subcommittee therefore decided to endorse the lower strength rifampicin + isoniazid combinations (60 mg + 30 mg and 60 mg + 60 mg) and rifampicin + isoniazid + pyrazinamide (60 mg + 30 mg + 150 mg) as probably useful for many children, but requested an urgent review of all clinical evidence to support these and other potential combinations.